202 related articles for article (PubMed ID: 17168718)
1. Targeting the EGFR pathway for cancer therapy.
Johnston JB; Navaratnam S; Pitz MW; Maniate JM; Wiechec E; Baust H; Gingerich J; Skliris GP; Murphy LC; Los M
Curr Med Chem; 2006; 13(29):3483-92. PubMed ID: 17168718
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
3. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Caponigro F
Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer.
Palayekar MJ; Herzog TJ
Int J Gynecol Cancer; 2008; 18(5):879-90. PubMed ID: 18053062
[TBL] [Abstract][Full Text] [Related]
6. Why the epidermal growth factor receptor? The rationale for cancer therapy.
Baselga J
Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
10. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
Herbst RS; Shin DM
Cancer; 2002 Mar; 94(5):1593-611. PubMed ID: 11920518
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
13. ErbB antagonists patenting: "playing chess with cancer".
Aifa S; Rebai A
Recent Pat Biotechnol; 2008; 2(3):181-7. PubMed ID: 19075865
[TBL] [Abstract][Full Text] [Related]
14. The ErbB receptor family: a therapeutic target for cancer.
de Bono JS; Rowinsky EK
Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
Zhu Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
[TBL] [Abstract][Full Text] [Related]
16. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
17. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
20. Canonical WNT signaling pathway and human AREG.
Katoh Y; Katoh M
Int J Mol Med; 2006 Jun; 17(6):1163-6. PubMed ID: 16685431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]